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ABSTRACT 
Peripheral nerve injuries can cause disabilities, social or economic problems. Melatonin, the secretory product of 
the pineal gland has antioxidant and anti-inflammatory actions. The aim of the present study was to investigate the 
effect of melatonin on the recovery of sciatic nerve after injury, comparing its effect when given in the light or the 
dark periods. Forty adult male Albino rats were allocated into four groups: control, nerve injury, nerve injury + 
melatonin given at light and nerve injury + melatonin given at dark. Nerve injury was initiated by clamping the 
sciatic nerve. Sciatic functional index (SFI) was measured preoperatively and postoperatively. Melatonin was 
given daily for six weeks. Recovery of the function was analyzed by functional analysis, electrophysiological 
analysis and biochemical measurement of Superoxide dismutase (SOD), Interleukin 1-beta (IL-1 β), Nerve growth 
factor (NGF), and bcl-2. Melatonin improved SFI, nerve conduction velocity (NCV) and the force of gastrocnem-
ius muscle contraction as compared to the untreated rats. SOD activity, NGF, and bcl-2 were significantly in-
creased, while IL-1β was significantly decreased after melatonin treatment as compared to the untreated injury 
group. SFI reached the control level; muscle contraction and IL-1B were significantly improved in the group 
treated with melatonin in the dark. Melatonin fastened the neural recovery and may be used in the treatment of 
nerve injury and it induced better nerve regeneration when the rats were treated during the dark period. 
 
Keywords: Melatonin, nerve injury, SFI, NCV 
 
 
 
INTRODUCTION 
Peripheral nerves are the most important 
structures for providing motor and sensory 
function. The peripheral nerve trauma re-
mains a major cause of motor disability and 
even with optimal surgical repair; clinically 
the outcome continues to be very poor (Khan 
et al., 2014). 
When damage occurs to a peripheral 
nerve, both ischemic and inflammatory pro-
cesses begin. As part of this process, free ox-
ygen radicals and many toxic agents accumu-
late around the site of injury resulting in cell 
destruction with the destruction of neurofila-
ments and microtubules. Many studies have 
been performed on surgical techniques; how-
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ever, studies on medications that might posi-
tively affect peripheral nerve regeneration are 
rare (Atik et al., 2011). 
Melatonin (N-acetyl-5-methoxytrypta-
mine) is secreted from the pineal gland, and 
its secretion is controlled by the circadian 
rhythm with the blood level being high during 
the dark period and low during the light pe-
riod. It is both a lipo- and hydrophilic mole-
cule, and it crosses all physical barriers in-
cluding the blood–brain barrier and plasma 
membrane (Zencirci et al., 2010). It is a prin-
cipal agent which has antioxidant, antiapop-
totic, anti-inflammatory (Reiter et al., 2007), 
and anticarcinogen properties for biological 
systems (Anisimov et al., 2006). 
Melatonin is notified that has neuropro-
tective effect by reducing nitric oxide synthe-
ses or scavenging free radicals' destructive ef-
fects in the nervous system (Anisimov et al., 
2006). Also, melatonin has been shown to be 
effective in arresting neurodegenerative phe-
nomena seen in experimental models of Alz-
heimer's disease, Parkinsonism and ischemic 
stroke (Mayo et al., 2005; Poeggeler et al., 
2008). 
According to the fore mentioned infor-
mation, we hypothesized a potential benefi-
cial role of melatonin in the treatment of pe-
ripheral nerve injury. We aimed at comparing 
the therapeutic effects of melatonin when 
given during the light and the dark period. We 
also hypothesized that such treatment could 
be partially based on reversing the mecha-
nisms associated with the development of 
nerve injury like oxidative stress, inflamma-
tory process, and apoptosis. 
 
MATERIALS AND METHODS 
Experimental design 
The experimental procedures, animal han-
dling, sampling, and scarification were done 
according to the “Guide for the care and use 
of laboratory animals” (NRC, 2011) and were 
approved by Ethical Committee of Physiol-
ogy Department, Faculty of Medicine, Cairo 
University.  
40 adult male Wistar Albino rats, 3–4 
months old weighing 150 to 200 g constituted 
the animal model for this study. The animals 
were housed one per cage (30×15×15cm) 
with free access to food and water. 
Animals were kept under constant labora-
tory conditions (e.g., 18 °C to 21 °C room 
temperature, humidity, and illumination of 
12 h cycles of light and darkness; light on at 
5:00 a.m., light off at 5:00 p.m.). 
Animals were randomly allocated into the 
following four groups (10 rats/group): 
Group I [Control group]. These rats were 
sham operated. They underwent surgical inci-
sion without sciatic nerve compression and 
were given the vehicle.  
Group II [The sciatic nerve injury (SNI) 
plus vehicle group]: The rats of this group re-
ceived an intraperitoneal (i.p) injection of the 
vehicle as a placebo after induction of the 
nerve injury.  
Group III [The SNI plus melatonin at light 
group]: In this group, sciatic nerve injury was 
performed and then the rats received melato-
nin (Sigma, USA), 50 mg/kg i.p, in the light 
period (Kaya et al., 2013b) at 9:00 am daily 
for 6 weeks. 
GroupIV [The SNI plus melatonin at dark 
group]: In this group, sciatic nerve injury was 
performed and then the rats received melato-
nin, 50 mg/kg i.p in the dark period (Kaya et 
al., 2013b) at 5:00 pm daily for six weeks. 
 
Surgical technique 
Under general anesthesia with xylazine (5 
mg/kg) ketamine (50 mg/kg) (Struck et al., 
2011), unilateral exposure of the left sciatic 
nerve at the upper border of the quadratus 
femoris is done for all the groups. An acute 
blunt injury was initiated by clamping the sci-
atic nerves with a standard temporary aneu-
rysmal clip for 2 minutes for all groups except 
the control one. Next, the clip was removed, 
the skin incision was sutured, and the animals 
were returned to their cages (Genovese et al., 
2005). 
 
Procedure of the work 
Before performing the nerve injury oper-
ation, the rats were tested for the sciatic func-
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tional index (SFI). Immediately after the pro-
cedure, the rats were tested again, and SFI 
was measured the 1st day after the operation 
and weekly throughout the period of the ex-
periment.  
After the experimental period of six 
weeks, the rats were tested on the walking 
track; then the rats were anesthetized with 
xylazine (5 mg/kg) ketamine (50 mg/kg) 
(Struck et al., 2011). Sciatic nerve and gas-
trocnemius muscle were exposed then NCV 
was measured in vivo by PowerLab, and the 
force of gastrocnemius muscle was measured 
by Intercept TSC286/1, also in vivo, immedi-
ately after measurement of NCV.  
Blood samples were taken from retro-or-
bital plexus by capillary tube and left to be 
clotted then centrifuged, and serum was sepa-
rated and kept frozen for analysis of Interleu-
kin 1-beta (IL-1 β). Rats were then sacrificed, 
and sciatic nerves were excised from their 
roots to the beginning of their branches. Each 
nerve was homogenized in phosphate buffer 
saline and was kept at -80 °C and was used for 
measurement of Superoxide Dismutase 
(SOD) activity, bcl2 expression, and Nerve 
growth factor (NGF) level. 
 
Footprint recording and analysis 
Preoperatively and continuing weekly 
throughout the duration of the study, func-
tional recovery was assessed by walking track 
analysis. For SFI, animals were tested in a 
confined walkway measuring 100 cm long 
and 7.5 cm wide with side wall height 15 cm 
(Kaya et al., 2013b). The hind paws of the rats 
were pressed down onto an inkpad, and they 
were allowed to walk along a sheet of white 
paper. The distances between the third toe and 
heel (Print Length "PL"), first and fifth toe 
(Toe Spread "TS") and second and fourth toe 
(Intermediate Toe Spread "ITS") were meas-
ured. For crushed leg, it was named as (Ex-
perimental Print Length "EPL", Experimental 
Toe Spread "ETS" and Experimental Interme-
diate Toe Spread "EITS") and for the control 
leg (Normal Print Length "NPL", Normal Toe 
Spread "NTS" and Normal Intermediate Toe 
Spread "NITS") respectively. 
The mean distances of three measure-
ments were used to calculate the following 
factors: 
 Toe spread factor (TSF): (ETS − NTS)/ 
NTS 
 Intermediate toe spread factor (ITSF): 
(EITS − NITS)/NITS 
 Print length factor (PLF): (EPL − NPL)/ 
NPL 
 SFI values were calculated by using the 
multiple linear regression formulae im-
proved by as follows: 
 SFI = −38.3 (PLF) + 109.5 (TSF) + 13.3 
(ITSF) − 8.8; where an SFI of 0 represents 
normal function, and an SFI of -100 
demonstrates complete functional loss 
(Monte-Raso et al., 2008). 
 
Nerve conduction velocity and force of 
muscle contraction 
Electrophysiological evaluation of nerve 
regeneration was performed in vivo at the end 
of the treatment under general anesthesia 
(Struck et al., 2011). Animals were anesthe-
tized; nerve conduction was measured by 
PowerLab (Yarar et al., 2015) in vivo after ex-
posure of sciatic nerve (which is mixed nerve 
with type A fibers). 
The force of contraction of gastrocnemius 
muscle was measured after six weeks, the left 
limb was fixed, skin opened, and after expo-
sure of sciatic nerve, the distal tendon of gas-
trocnemius muscle was sectioned and at-
tached to a force transducer to induce isomet-
ric contraction (Intercept TSC286/1). The 
output signals were then fed to a bipotential 
amplifier (Intercept) and displayed using per-
sonal computer-based data capture and acqui-
sition software (Phys 4 intercept).  
The muscle was activated with electrodes 
stimulating the nerve using monophasic rec-
tangular pulses of a 0.2-millisecond duration 
of the anodal current. Adjustments to muscle 
length were made to find the optimal length 
for maximum twitch force. Stimulus intensity 
was increased until maximum twitch force 
was obtained. The Twitch Tension (TT) (ex-
pressed as screen units) was recorded Using 
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screen cursors from each gastrocnemius mus-
cle (Chen and Always, 2000). 
 
Biochemical analysis 
Sample preparation 
60 mg of the sciatic nerve was homoge-
nized in phosphate buffer saline then centri-
fuged at 10000 rpm for 20 min then the super-
natant was kept frozen at -80 °C until used for 
subsequent analysis of SOD activity, bcl2 
gene expression, and NGF level. 
The assay was based on the ability of SOD 
to inhibit the auto-oxidation of epinephrine at 
alkaline pH. The mitochondrial suspension 
(0.2 ml) was treated with 0.8 ml of 50 mmol/ 
l glycine buffer (pH 10.4) and 0.020 ml epi-
nephrine. SOD activity was measured kinet-
ically at 480 nm. The activity was measured 
indirectly by the oxidized product of epineph-
rine. MnSOD activity was expressed as nano-
moles of (-) epinephrine protected from oxi-
dation per minute per milligram protein by us-
ing a molar extinction coefficient of 4020M-
1 cm-1 (Nishikimi et al., 1972).  
Detection of bcl2 gene expression was 
performed by Real time-Polymerase Chain 
Reaction (real time-PCR): 
a. Total RNA extraction 
Total RNA was extracted from tissues us-
ing TRIzol method according to the manufac-
turer’s protocol. In brief, RNA was extracted 
by homogenization in TRIzol reagent (Invi-
trogen, Life Technologies, USA). The ho-
mogenate was then incubated for 5 min at 
room temperature. A 1:5 volume of chloro-
form was added, and the tube was vortexed 
and centrifuged at 12 000 g for 15 min. 
The aqueous phase was isolated, and the 
total RNA was precipitated with absolute eth-
anol. After centrifugation and washing, the to-
tal RNA was finally eluted in 20 μL of the 
RNase-free water. The RNA concentrations 
and purity were measured with an ultraviolet 
spectrophotometer. 
b. Complementary DNA (cDNA) synthesis  
The cDNA was synthesized from 1 μg 
RNA using SuperScript III First-Strand Syn-
thesis System as described in the manufactur-
er's protocol (Invitrogen, Life Technologies). 
In brief, one μg of total RNA was mixed with 
50 μM oligo (dT)20, 50 ng/μL random pri-
mers, and ten mM dNTP mix in a total volume 
of 10 μL. The mixture was incubated at 56 °C 
for 5 min, then placed on ice for 3 min. The 
reverse transcriptase master mix containing 2 
μL of 10× RT buffer, 4 μL of 25 mM MgCl2, 
2 μL of 0.1 M DTT, and 1 μL of SuperScript® 
III RT (200 U/μL) was added to the mixture 
and was incubated at 25 °C for 10 min fol-
lowed by 50 min at 50 °C. 
c. Real-time quantitative PCR  
The relative abundance of mRNA species 
was assessed using the SYBR Green method 
on an ABI prism 7500 sequence detector sys-
tem (Applied Biosystems, Foster City, CA). 
PCR primers (shown in Table 1) were de-
signed with Gene Runner Software (Hasting 
Software, Inc., Hasting, NY) from RNA se-
quences from GenBank. All primer sets had a 
calculated annealing temperature of 60 °C. 
Quantitative RT-PCR was performed in a 25-
μl reaction volume consisting of 2X SYBR 
Green PCR Master Mix (Applied Biosys-
tems), 900 nM of each primer and 2-3 μl of 
cDNA. Amplification conditions were 2 min 
at 50 °C, 10 min at 95 °C and 40 cycles of de-
naturation for 15 s and annealing/extension at 
60 °C for 10 min. Data from real-time assays 
were calculated using the v1·7 Sequence De-
tection Software from PE Biosystems (Foster 
City, CA). Relative expression of studied 
gene mRNA was calculated using the com-
parative Ct method. All values were normal-
ized to the beta actin gene and reported as fold 
change over background levels detected in 
diseases group (Livak and Schmittgen, 2001). 
Analysis of serum IL-1β performed by 
ELISA kit (R&D system, USA) according to 
manufacturer instructions.  
NGF Level in Sciatic Nerve Tissue meas-
ured using Boster's rat NGF ELISA Kit is 
based on standard sandwich enzyme-linked 
immune sorbent assay technology (Sanico et 
al., 2000) according to manufacturer instruc-
tions. 
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Statistical methods 
Data were coded and entered using the 
statistical package SPSS version 22. Data was 
summarized using mean ± standard deviation. 
Comparisons between groups were made us-
ing analysis of variance (ANOVA) with mul-
tiple comparisons Bonferroni post hoc test in 
normally distributed quantitative variables 
while non-parametric Kruskal-Wallis test and 
Mann-Whitney test were used for non-nor-
mally distributed quantitative variables 
(Chan, 2003). P-values less than 0.05 were 
considered as statistically significant (Chan, 
2003). 
RESULTS 
Results of SFI 
Motor performance of the studied groups 
in the walking track represented by SFI is 
shown in Table 2: in the untreated nerve in-
jury group, a significant (P ≤ 0.05) impair-
ment in the motor function was manifested 
since the 1st day after the injury. This impair-
ment continued throughout the time of the ex-
periment and showed some gradual improve-
ment throughout the experiment but remained 
significantly (P ≤ 0.05) impaired as compared 
to the control group till the end of the 6th 
week. 
 
 
Table 1: Sequence of the primers used for real-time PCR for bcl-2 measurement 
Parameter Primer sequence 
Bcl2 5'-CACCCCTGGCATCTTCTCCTT-3' (sense)  5'-AGCGTCTTCAGAGACAGCCAG-3' (antisense) 
Actin F: (forward) TGTTTGAGACCTTCAACACC R:(reverse)TAGGAGCCAGGGCAGTAATC 
 
Table 2: Comparison of SFI between control, nerve injury, melatonin light and melatonin dark groups 
preoperatively, 1st day postoperative, and throughout six weeks 
 Control Untreated Nerve Injury Melatonin Light Melatonin Dark
Preoperative -7.73 ± 1.22 -8.03 ± 1.23 -7.70 ± 1.19 -7.63 ± 1.19 
Percent change %   -4.11 -4.98 
1st day post-operative -7.73 ± 1.22 -83.08 ± 6.54 * -81.18 ± 4.85 * -79.96 ± 7.06 * 
Percent change %   -2.29 -3.76 
1st week -7.73 ± 1.22 -73.63 ± 4.46 * -70.33 ± 6.11 * -67.93 ± 10.10 *
Percent change %   -4.48 -7.74 
2nd week -7.73 ± 1.22 -70.84 ± 5.35 * -59.72 ± 6.97 *# -58.21 ± 8.01 *#
Percent change %   -15.7 -17.83 
3rd week -7.73 ± 1.22 -62.72 ± 9.99 * -52.99 ± 9.68 * -51.68 ± 11.75 *
Percent change %   -15.51 -17.6 
4th week -7.73 ± 1.22 -54.33 ± 10.97 * -42.81 ± 6.63 * -41.47 ± 8.42 *#
Percent change %   -21.2 -23.67 
5th week -7.73 ± 1.22 -52.24 ± 10.35 * -34.98 ± 7.06 *# -31.35 ± 552 *#
Percent change %   -33.04 -39.99 
6th week -7.73 ± 1.22 -50.80 ± 10.19 * -21.37 ± 4.48 *# -16.01 ± 3.63 #
Percent change %   -57.93 -68.48 
Values expressed as mean ± SD; percent change is represented as compared to nerve injury group: * Statistically significant 
compared to the corresponding value in the control group, # statistically significant compared to the corresponding value in the 
nerve injury group, $ statistically significant compared to the corresponding value in the melatonin light group at P ≤ 0.05. 
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There wasn't any significant (P ≤ 0.05) 
difference between melatonin light and un-
treated nerve injury group till the 1st week. 
From the 2nd week to the 6th one, there was 
significant (P ≤ 0.05) improvement of SFI in 
the melatonin light group (except 3rd, 4th 
weeks) as compared to the untreated nerve in-
jury group.  
There wasn't any significant (P ≤ 0.05) 
difference between the melatonin dark and the 
untreated nerve injury group till the 1st week 
as compared to the untreated nerve injury 
group. But from the 2nd week to the 6th one 
there was significant (P ≤ 0.05) improvement 
of SFI in the melatonin dark group (except 3rd 
week) as compared to the untreated nerve in-
jury group. There wasn't any significant 
(P ≤ 0.05) difference between melatonin light 
and melatonin dark groups throughout the six 
weeks. 
 
Results of nerve conduction velocity and 
force of muscle contraction 
Recording of nerve conduction velocity in 
the studied groups (Figure 1) reveals that: in-
duction of sciatic nerve injury caused a signif-
icant (P ≤ 0.05) impairment in NCV as com-
pared to the control. The significant 
(P ≤ 0.05) impairment continued throughout 
the time of the experiment. Melatonin given 
at the light period enhanced the recovery with 
a significant (P ≤ 0.05) increase in NCV com-
pared to untreated nerve injury group. Mela-
tonin dark group was improved as there was a 
significant (P ≤ 0.05) increase in NCV values 
as compared to the untreated nerve injury 
group and this improvement approximated 
the control value. There wasn't any significant 
(P ≤ 0.05) difference between melatonin light 
and melatonin dark groups. 
Induction of nerve injury caused a signif-
icant (P ≤ 0.05) decrease in the force of con-
traction of Gastrocnemius muscle in the un-
treated nerve injury group, and this significant 
decrease continued throughout the time of the 
experiment compared to the control group. 
There was significant (P ≤ 0.05) improve-
ment of the force of muscle contraction in the 
melatonin light group compared to nerve in-
jury group and this improvement approxi-
mated the control value. In the melatonin, 
dark group the force of gastrocnemius muscle 
contraction was highly improved, and its 
mean value significantly (P ≤ 0.05) increased 
as compared to control and there was signifi-
cant (P ≤ 0.05) improvement of the force of 
muscle contraction as compared to the un-
treated nerve injury group (Figure 2).  
 
 
 
Figure 1: Comparison of NCV between control, 
nerve injury, melatonin light and melatonin dark 
groups at the end 6th week of the experiment. Val-
ues expressed as mean ± SD. *: statistically sig-
nificant compared to the corresponding value in 
the control group, #: statistically significant com-
pared to the corresponding value in the nerve in-
jury group; $: statistically significant compared to 
the corresponding value in the melatonin light 
group at P ≤ 0.05. 
 
 
 
Figure 2: Comparison of muscle contraction be-
tween control, nerve injury, melatonin light and 
melatonin dark groups at the end 6th week of the 
experiment. Values expressed as mean ± SD,*: 
statistically significant compared to the corre-
sponding value in the control group, #: statistically 
significant compared to the corresponding value 
in the nerve injury group, $: statistically significant 
compared to the corresponding value in the mel-
atonin light group at P ≤ 0.05. 
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Biochemical results 
Evaluation of biochemical markers in the 
studied groups (Table 3) shows that: 
 Induction of nerve injury caused signifi-
cant impairment in SOD activity as com-
pared to the control throughout the time of 
the experiment. In the melatonin light 
group, there was significant (P ≤ 0.05) 
improvement of its activity as compared 
to the untreated nerve injury group. In the 
melatonin dark group, there was a signifi-
cant (P ≤ 0.05) improvement of SOD ac-
tivity compared to the untreated nerve in-
jury group. There wasn't any significant 
difference between melatonin light and 
melatonin dark groups as regards SOD ac-
tivity. 
 There was a significant (P ≤ 0.05) in-
crease in the serum IL-1β level after the 
end of the 6th week and the mean for the 
untreated nerve injury group as compared 
to the control. In melatonin light group 
there was a significant (P ≤ 0.05) decrease 
in the serum level of IL-1β as compared to 
the untreated nerve injury group. Also; in 
the melatonin dark group, there was a sig-
nificant (P ≤ 0.05) decrease in the serum 
level of IL-1β as compared to the un-
treated nerve injury group.  
 The apoptotic regulator bcl2 gene expres-
sion was significantly (P ≤ 0.05) de-
creased in the untreated nerve injury as 
compared to the control. Melatonin treat-
ment at light caused a significant increase 
in bcl-2 expression as compared to the un-
treated nerve injury group. Furthermore; 
in the group treated with melatonin at 
dark, there was a significant (P ≤ 0.05) in-
crease of bcl-2 expression as compared to 
the untreated nerve injury group. There 
wasn't any significant (P ≤ 0.05) differ-
ence between melatonin light and melato-
nin dark group. 
 There was a significant (P ≤ 0.05) in-
crease in NGF level in the injured sciatic 
nerve as compared to the control at the 6th 
week as compared to the control. Melato-
nin treatment during both light and dark 
periods caused significant (P ≤ 0.05) in-
crease of NGF compared to untreated 
nerve injury group. There wasn't any sig-
nificant (P ≤ 0.05) difference between 
melatonin light and melatonin dark group. 
 
DISCUSSION 
SFI in untreated and melatonin-treated 
groups 
Analysis of rat walking tracks by SFI has 
proven to be a reliable, repeatable, economi-
cal, and quantitative method of evaluating 
function following sciatic nerve injury and re-
pair. Motor function, mainly measured by the 
SFI can directly reflect nerve function follow-
ing peripheral nerve injury (Pan et al., 2009). 
 
Table 3: Comparison of biochemical parameters in the studied groups at the end 6th week of the ex-
periment 
Parameter Control Nerve Injury Melatonin Light Melatonin Dark
SOD (u/mg)  2.91 ± 0.23 0.38 ± 0.09 * 1.52 ± 0.71 *# 2.05 ± 0.64 *# 
Percent change%   300 439.47 
IL.1β (pg/ml) 34.18 ± 4.35 119.46 ± 13.25 * 75.98 ± 12.53 *# 48.75 ± 9.57 #$ 
Percent change%   -36.4 -59.19 
bcl2 relative expression 1.11 ± 0.28 0.27 ± 0.05 * 0.65 ± 0.14 *# 0.82 ± 0.19 *# 
Percent change %   140.74 203.7 
NGF (pg/ml) 49.69 ± 8.05 105.80 ± 12.84 * 155.55 ± 30.36*# 180.55 ± 23.84*#
Percent change %   47.02 70.65 
Values expressed as mean ± SD; percent change is represented as compared to nerve injury group: * statistically significant 
compared to the corresponding value in the control group, # statistically significant compared to the corresponding value in the 
nerve injury group, $: statistically significant compared to the corresponding value in the melatonin light group at P ≤ 0.05.  
EXCLI Journal 2017;16:138-150 – ISSN 1611-2156 
Received: November 09, 2016, accepted: January 03, 2017, published: March 06, 2017 
 
 
145 
The results of the present study showed 
that there was significant impairment in SFI 
since the 1st day after the injury and continued 
throughout the time of the experiment. This 
finding is in agreement with previous studies 
(Galloway et al., 2005; Sozcukler et al., 2013; 
Khan et al., 2014). 
The effect of nerve injury on SFI was sec-
ondary to the loss of ankle plantar flexion, 
foot inverters, toe flexors, and foot intrinsics, 
so the footprint characteristically demon-
strates an increased print length, a decreased 
toe spread, and a decreased intermediate toe 
spread (Sarikcioglu et al., 2009). 
In the current study; melatonin treatment 
significantly accelerated the recovery process 
in the melatonin-treated groups as compared 
to the vehicle-treated group (nerve injury) 
group. The group of rats treated with melato-
nin at the dark period showed a significantly 
better performance in SFI test compared to 
that treated during the light period. 
In agreement with our results; studies con-
ducted by Zencirci et al. (2010), and Atik et 
al. (2011) reporting that the SFI value was in-
creased significantly in the melatonin-treated 
groups as compared to the untreated group of 
rats with peripheral nerve crush injury. Im-
provement of SFI indicates better motor and 
sensory function revealing nerve and muscle 
regeneration as suggested by Sarikcioglu et 
al. (2009).  
These beneficial effects of melatonin ad-
ministration on SFI effects may be attributed 
to its antioxidant and anti-inflammatory prop-
erties improving the neural recovery after the 
injury (Kaya et al., 2013a).  
 
Nerve conduction velocity and force of 
muscle contraction in untreated and mela-
tonin-treated groups 
Nerve conduction, the primary function of 
peripheral nerves, can be directly reflected by 
the conduction velocity of the electrical activ-
ity of the neural stem (Yang et al., 2007). The 
results of the present study showed that nerve 
injury significantly decreased NCV, this by 
Dai et al. (2015), and Yarar et al. (2015), who 
found decreased NCV eight weeks after in-
duction of nerve injury. 
It was reported that the myelin sheath is a 
rich source of lipids and is the main target of 
free radical-mediated lipid peroxidation dur-
ing trauma causing not only damage to the 
phospholipids of the neural membranes but 
also makes myelin proteins more susceptible 
to the attack of reactive oxygen species (Sho-
kouhi et al., 2008).  
Moreover, the findings of the present 
study showed that the force of muscle con-
traction was significantly decreased after 
nerve injury as compared to the control. These 
results were agreed by Maciel et al. (2013), 
and Zhao et al. (2012). On the other hand, Te-
odori et al. (2011), suggested preservation of 
muscle contraction after rat sciatic nerve 
crush between the 10th and 15th day after the 
injury. 
Denervated muscles undergo progressive 
degeneration, which leads to loss of muscle 
fibers and their replacement with fat and fi-
brous connective tissue and this decreases the 
force of its contraction (Rochkind et al., 
2009). Also, with prolonged denervation, the 
motor end plate area gradually reduced lead-
ing to a reduction of the force of muscle con-
traction (Zhao et al., 2012). 
In the current work, melatonin treatment 
for six weeks induced a significant increase of 
NCV in the melatonin-treated groups as com-
pared to the untreated nerve injury group, re-
vealing a beneficial effect of melatonin treat-
ment. The increased NCV in the melatonin-
treated groups reached approximately the val-
ues recorded in the control group, with no sig-
nificant difference shown between the mela-
tonin-treated groups and the control group. 
In accordance with our results, Atik et al. 
(2011) reported that melatonin treatment (10 
mg/kg for 21 days) significantly increased 
NCV compared with the untreated group. 
It appears that melatonin helps develop-
ment and maturation of myelin sheath of the 
regenerated nerve or protects it from peroxi-
dation and limits its damage (Shokouhi et al., 
2008). 
EXCLI Journal 2017;16:138-150 – ISSN 1611-2156 
Received: November 09, 2016, accepted: January 03, 2017, published: March 06, 2017 
 
 
146 
Moreover, the results of the present study 
showed that melatonin treatment increased 
the force of muscle contraction significantly 
as compared to the untreated nerve injury 
group to return approximately as the mean 
values recorded in the control group. The 
group treated with melatonin at the dark pe-
riod showed a significant increase in muscle 
contraction force as compared to that treated 
at the light period revealing the beneficial ef-
fect of melatonin treatment especially when 
given at the dark period. 
This finding was consistent with Chang et 
al. (2014), who induced an in vivo model of 
peripheral nerve injury and administered Mel-
atonin for 30 days. The proliferative effects of 
melatonin on Schwann cells are closely re-
lated to the improved nerve recovery, increas-
ing the number of reinnervated motor end 
plates on target muscles following PNI lead-
ing to increasing the force of muscle contrac-
tion (Chen et al., 2007). 
Interestingly, Nassar et al. (2007) showed 
that taking up to 5 milligrams of melatonin 
before sleep or during wakeful hours results 
in increased blood growth-hormone levels. 
This observation supports our results that the 
group treated with melatonin at the dark 
showed a significant increase in muscle con-
traction as compared to control forming a link 
between blood melatonin levels and GH re-
lease. 
 
Biochemical markers in untreated and mel-
atonin-treated groups 
The observations of the present study also 
showed that nerve injury decreased SOD ac-
tivity in the injured nerve tissue as compared 
to the control group indicating that crush in-
jury to the sciatic nerve causes oxidative 
stress. These results were in agreement with 
previous studies on peripheral nerve injury 
(Atilgan et al., 2014; Kucu et al., 2015). 
Radical-scavenging antioxidants such as 
SOD which is concerned with the removal of 
superoxide anion and peroxide are consumed 
by the increased free radical activity. Oxida-
tive stress increases after nerve injury and 
may be a mechanism of it (Senoglu et al., 
2009).  
Moreover, the present work showed that 
nerve injury induced a significant increase in 
serum IL-1β level as compared to the control 
indicating that nerve injury leads to activation 
of an inflammatory response. This result was 
in agreement with Ellis and Bennett (2013) 
and Ydens et al. (2012)  
The first cells to react to damage of the 
nerve are Schwann cells and resident immune 
cells. An unspecified signal from damaged 
axons results in activation of the extracellular 
signal-related mitogen-activated protein ki-
nase signaling pathway; triggering the expres-
sion of inflammatory mediators and recruiting 
immune cells to the damaged nerve (Napoli et 
al., 2012). These inflammatory mediators 
control phospholipase-A2 activation in 
Schwann cells which is responsible for initial 
degradation of myelin (Martini et al., 2008).  
Perrin et al. (2005), reported that the ad-
ministration of a function-blocking antibody 
against IL-1β into the injured mouse sciatic 
nerve prevented a reduction in the recruitment 
of macrophages and retarded myelin phago-
cytosis.  
Furthermore; the findings of the present 
study showed that the expression of bcl2 in 
the injured sciatic nerve significantly de-
creased as compared to the control. Kotulska 
et al. (2005) suggested that the expression of 
bcl-2 is closely related to the recovery and vi-
ability of neurons after peripheral nerve injury 
as well as fiber regeneration and myelination. 
The results of the present study also 
showed that nerve injury increased NGF level 
in the nerve tissue as compared to control. 
This finding was in agreement with a study by 
Richner et al. (2014) who confirmed that the 
levels of NGF exhibit a biphasic response to 
axotomy with an immediate early rise in NGF 
peaking six h after injury. Following nerve in-
jury, a large quantity of production of NGF by 
fibroblasts, Schwann cells, and macrophages, 
is triggered by cytokines released from en-
dogenous or exogenous phagocytes (Jing et 
al., 2009). 
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The observations of the present study 
proved that melatonin, administration either 
at the light or dark periods, improved or fas-
tened recovery of nerve injury. Trying to ex-
plain the underlying mechanisms for this ben-
eficial effect, we evaluated the antioxidant ac-
tivity of melatonin through measuring and 
comparing SOD activity in nerve tissue in the 
different groups. We demonstrated that mela-
tonin administration significantly increased 
SOD activity in the melatonin-treated groups 
compared to untreated nerve injury group. 
There was no significant difference between 
the group of rats treated with melatonin dur-
ing the dark period and that treated during the 
light period. These results were in agreement 
with those reported by Kaya et al. (2013a), 
who reported that melatonin treatment ele-
vated SOD activity in sciatic nerve samples in 
rats after both cut and crush injury. 
Melatonin has profound antioxidant ac-
tions against oxidative and nitrosative stress 
(Esposito and Cuzzocrea, 2010), and is highly 
effective in scavenging reactive oxygen and 
nitrogen species. Moreover, melatonin is 
known to be a stabilizer of cell and organelle 
membranes because of its inhibitory effects 
on lipid peroxidation as explained by Reiter et 
al. (2001).  
Another mechanism explaining the pro-
tective effect of melatonin and its potential 
role in accelerating the recovery after nerve 
injury is through reducing the inflammatory 
response associated with the nerve injury. The 
results of the present study showed that mela-
tonin significantly decreased IL-1β level in 
serum as compared to the untreated nerve in-
jury group. The group treated with melatonin 
at the dark period showed significantly more 
improvement than that treated at the light pe-
riod revealing the beneficial effect of melato-
nin treatment especially when given at the 
dark period. 
Melatonin treatment reduced the elevated 
levels of proinflammatory cytokines like 
TNF-α and IL-6, in sciatic nerves of rats. The 
effect of melatonin on IL-1β has also been 
evaluated in many other tissues, and it was 
shown that melatonin decreases IL1β as in 
brain ischemia induced by blockade of the 
right middle cerebral artery in aging male 
Wistar rats (Paredes et al., 2015).  
Moreover, the present work showed that 
the antiapoptotic marker bcL-2 expression 
was significantly elevated in the melatonin-
treated groups as compared to untreated nerve 
injury group; however, it was still signifi-
cantly decreased as compared to the control 
group.  
The antiapoptotic effect of melatonin was 
also reported by Paredes et al. (2015) who re-
vealed a significant elevation in the mRNA 
levels of Bcl-2. Some studies have suggested 
that melatonin inhibits apoptotic processes 
via its antioxidant properties as reported by 
Sainz et al. (2003). Other studies have shown 
that the anti-apoptotic effects of melatonin are 
accompanied by modulation of the expression 
of the Bcl-2 family genes (Rubio et al. (2007). 
Melatonin treatment because of antioxidative 
and antiapoptotic properties provide benefi-
cial effects on NGF. Melatonin also increases 
neurotrophic factors by activating its recep-
tors (MT1 and MT2) (Kong et al. (2008). 
 
Conclusions and recommendations 
From the previous data, it was shown that 
melatonin is vital in the treatment of nerve in-
jury and helping in neural regeneration by its 
antioxidant, anti-inflammatory and antiapop-
totic actions. There was no significant differ-
ence when it was given in the light or dark pe-
riod except in improvement of muscle con-
traction and IL-1β which were significantly 
improved in the dark period. Also, SFI 
reached the control level in the group treated 
with melatonin in the dark. These effects may 
be due to the physiological circadian rhythm 
of it in the body as it is mainly secreted by the 
pineal gland in the dark. Melatonin also pre-
vents the adrenal gland from responding to 
ACTH and inhibit cortisol secretion, so when 
given in the light, it inhibits cortisol secretion 
affecting its anti-inflammatory action (Rich-
ter et al., 2008).  
We conclude that; treatment of nerve in-
jury with melatonin helped in fastening the re-
covery of the injured nerves with significant 
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improvement of the functional, electrophysi-
ological and biochemical parameters of them. 
This improvement of nerve regeneration can 
be explained by the antioxidant, anti-apop-
totic and anti-inflammatory effect of melato-
nin hormone and its role in enhancing recov-
ery through stimulating NGF. The different 
time of melatonin administration gave differ-
ent results in nerve regeneration suggesting 
that giving it at the dark period was better than 
giving it during the light period and this may 
be explained by the physiological circadian 
rhythm of melatonin as it is naturally secreted 
in the dark period in the body. 
Further studies are recommended with 
evaluation of more parameters indicating 
changes in the muscle and sciatic nerve that 
are not measured in our work to explain the 
beneficial effect of melatonin on enhanced 
functional recovery recorded in the group 
with melatonin treatment at the dark period 
compared to those treated with the same dose 
but at the light period.  
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